SCHEMBL6534202

SCHEMBL6534202

CC(=O)C1(C(C)=O)[C@H](O)[C@@H](CO)O[C@@]1(C(C)=O)n1ccc(N)nc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.45
PDE4D Q08499 1/20 0.45
SLC29A1 Q99808 1/20 0.45
LMNA P02545 5/20 0.45
MTOR P42345 2/20 0.45
THRB P10828 1/20 0.45
MDM2 Q00987 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
CACNA1F O60840 2/20 0.36
ALB P02768 2/20 0.36
MAPT P10636 2/20 0.36
CACNA1D Q01668 2/20 0.36
CACNA1S Q13698 2/20 0.36
CACNA1C Q13936 2/20 0.36
POLA1 P09884 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
FGFR1 P11362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27321202 0.88 PDE3A (0.44) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL31189348 0.87 PDE3A (0.48) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL29414447 0.85 PDE3A (0.42) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL381848 0.84 PDE3A (0.41) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1629190 0.81 PDE3A (0.43) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL10615248 0.81 PDE3A (0.44) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL4747644 0.78 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL236109 0.78 PDE3A (0.48) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL27617191 0.77 PDE3A (0.41) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL8627861 0.76 PDE3A (0.44) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORPORATION (US) 2004-09-30 US disclosed
US-6743782-B1 ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY WELLSTAT THERAPEUTICS CORPORATION 2004-06-01 US disclosed
US-6020320-A Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 2000-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof UNG, OGG1, NQO1 PDE3A 1579/4885PDE4D 552/4885SLC29A1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.